KRSNAAKrsnaa Diagnostics

₹772.8-2.19%

Market Cap

₹2,496.48 Cr

Stock P/E

31.12

ROCE

12.39%

ROE

9.22%

Book Value

₹276.50

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Strong FY25 operating performance with revenue growth, EBITDA margin expansion, and higher patient/test volumes.
•
Significant PPP/PPP-led growth in public healthcare with a high win-to-bid ratio in free diagnostic initiatives.

NEGATIVES

•
Execution risk in radiology ramp-up due to Maharashtra CT MRI delays and revised BMC tender not pursued.
•
Receivables cycle remains elevated, with HP/Karnataka contributing to 128-day overall receivable days.

Peers Summary

Growth Outperformer

Krsnaa Diagnostics Ltd. showcases strong growth metrics with solid profitability ratios compared to its peers, making it a notable performer within the Hospital & Healthcare Services sector. Its manageable debt levels and efficient cash flow further enhance its investment appeal.

Key Points

• Krsnaa Diagnostics Ltd. has the highest revenue growth YoY among peers at 15.74%.
• With a PE ratio of 31.22, Krsnaa is well-valued compared to peers like Fortis and Max Healthcare.
• The company boasts a healthy debt-equity ratio of 0.2322, indicating low financial risk.

Top Performers

Global Health Ltd.

Highest revenue growth YoY at 21.56%.

Narayana Hrudayalaya Ltd.

Highest ROE at 24.27%.

Aster DM Healthcare Ltd.

Lowest PE at 5.05, indicating strong value.

Explore

Watchlists

Command Palette